Agenus to Host Research and Development Day on May 14, 2015
May 08 2015 - 7:00AM
Business Wire
Agenus Inc. (NASDAQ: AGEN), today announced additional details
for the Company’s upcoming analyst and institutional investor
meeting to be held on Thursday, May 14, 2015, from 4:30
to 6:30 PM Eastern Time in New York City. The event
will provide an overview of the Company’s
proprietary and partnered pipeline, including its antibody
platforms and checkpoint modulator programs, its heat shock
protein-based vaccine platform and its saponin-based vaccine
adjuvant platform. Management will also provide an update on its
strategic alliances, including those with Incyte and Merck, and its
recent strategic acquisition, all within the framework of its
overall corporate strategy.
The event will be moderated by Garo Armen, Ph.D., the Company’s
Chief Executive Officer, and Robert Stein, M.D., Ph.D., the
Company’s Chief Scientific Officer, and will include presentations
by key opinion leaders in immuno-oncology, followed by an in depth
panel discussion and a question and answer session.
Presenters will include:
- Charles Drake, M.D., Ph.D., Co-Director
at the Prostate Cancer Multidisciplinary Clinic and Associate
Professor of Oncology, Urology, and Immunology at the Johns Hopkins
School of Medicine. Dr. Drake is a leading authority on checkpoint
modulators and will address recent progress, as well as key
challenges and opportunities in the immuno-oncology field involving
both antibody and vaccine therapeutics.
- Orin Bloch, M.D., Khatib Professor of
Neurological Surgery at Northwestern University Feinberg School of
Medicine. Dr. Bloch is a leading authority on brain cancer, and was
a senior investigator in the Phase 2 study of Agenus’ Prophage
vaccine in newly diagnosed glioblastoma multiforme (GBM). He will
present an overview of the treatment landscape in GBM, as well as a
summary of the most recent data on Prophage.
A live webcast will be accessible from the Company’s website at
www.agenusbio.com/webcast/. Portions of the event will be available
for replay on the company’s website.
About Agenus
Agenus is an immunology company developing a series of
Checkpoint Modulators for the treatment of patients with cancer,
infectious diseases, and other immune disorders, heat shock protein
(HSP)-based vaccines, and immune adjuvants. These programs are
supported by three separate technology platforms. Agenus’ internal
and partnered checkpoint modulator programs target GITR, OX40,
CTLA-4, LAG-3, TIM-3, PD-1 and other undisclosed programs. The
company’s proprietary discovery engine Retrocyte DisplayTM is
used to generate fully human and humanized therapeutic antibody
drug candidates. The Retrocyte Display platform uses a
high-throughput approach incorporating IgG format human antibody
libraries expressed in mammalian B-lineage cells. Agenus recently
acquired a powerful yeast antibody display platform termed SECANT,
developed by Celexion, LLC. SECANT allows rapid generation of
soluble, full-length human antibodies. SECANT and Agenus’ mammalian
antibody display platform have complementary strengths and further
bolster Agenus' abilities to generate and optimize fully human
monoclonal antibodies. Agenus’ heat shock protein-based vaccines
have completed Phase 2 studies in newly diagnosed glioblastoma
multiforme, and in the treatment of herpes simplex viral infection;
the heat shock protein-based vaccine platform can generate
personalized as well as off the shelf products. The company’s QS-21
Stimulon® adjuvant platform is extensively partnered with
GlaxoSmithKline and with Janssen Sciences Ireland UC and includes
several candidates in Phase 2 trials, as well as shingles and
malaria vaccines which have successfully completed Phase 3 clinical
trials. For more information, please visit www.agenusbio.com,
or connect with the company on Facebook, LinkedIn, Twitter and
Google+; information that may be important to investors will be
routinely posted in these locations.
Forward-Looking Statement
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding the Company’s
upcoming analyst and institutional investor meeting. These
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially. These risks
and uncertainties include, among others, the factors described
under the Risk Factors section of our most recent Quarterly Report
on Form 10-Q or annual report on Form 10-K filed with the
Securities and Exchange Commission. Agenus cautions investors not
to place considerable reliance on the forward-looking statements
contained in this release. These statements speak only as of the
date of this press release, and Agenus undertakes no obligation to
update or revise the statements, other than to the extent required
by law. All forward-looking statements are expressly qualified in
their entirety by this cautionary statement.
Media:BMC CommunicationsBrad Miles,
646-513-3125bmiles@bmccommunications.comorInvestors:Argot
PartnersAndrea Rabney, 212-600-1902andrea@argotpartners.comorJamie
Maarten, 212-600-1902jamie@argotpartners.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024